ADVERTISEMENT

Ireland

Global Pharma Guidance Tracker – September 2024

Global Pharma Guidance Tracker – September 2024

Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

People On The Move: Appointments At Norgine, IPHA, Orifarm

People On The Move: Appointments At Norgine, IPHA, Orifarm

Leadership changes at Norgine, IPHA and Orifarm feature in this week's round-up of European consumer health people news.

Global Medtech Guidance Tracker: September 2024

Global Medtech Guidance Tracker: September 2024

Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 40 documents have been posted on the tracker since its last update.

Perrigo’s Tab Owed To Shareholders Nine Years After Spurning Mylan’s Hostile Takeover? $97M

Perrigo’s Tab Owed To Shareholders Nine Years After Spurning Mylan’s Hostile Takeover? $97M

An end to litigation filed by institutional investors, insurance companies and pension funds comes four CEOs after Perrigo's chief exec during Mylan's tender in 2015, Joseph Papa, resigned to lead another firm in 2016. Plaintiff attorneys are asking for up to 20% of settlement in fees.

Ireland Steps Up Efforts To Boost Clinical Trial Performance By Standardizing CTAs

Ireland Steps Up Efforts To Boost Clinical Trial Performance By Standardizing CTAs

Standard templates for clinical trial agreements are expected to help do away with the costs and delays arising from the use of different versions in Ireland.

Perrigo’s Consumer Health Brand Talk Gets An Executive Voice With First Brand Chief Appointed

Perrigo’s Consumer Health Brand Talk Gets An Executive Voice With First Brand Chief Appointed

David Ball moves from Bayer’s North America business to be Perrigo’s first chief brand and digital officer. He joins CEO who also moved to Perrigo from Bayer with decades of branded product experience.

Perrigo Q2 Results Down Nearly 11% On Formula Slump Despite Women’s Health Sales Jump On Opill

Perrigo Q2 Results Down Nearly 11% On Formula Slump Despite Women’s Health Sales Jump On Opill

OTC private label/store brand product giant’s Q2 net sales down 10.7% to $1.1bn, but women’s health product sales jump 31.4% largely on Opill launched late in Q1. Biggest hit to results from infant formula business, down a reported 82% due to ongoing manufacturing quality-control remediation.

Global Pharma Guidance Tracker – June 2024

Global Pharma Guidance Tracker – June 2024

Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

Another Funding Win For Chiesi In Europe As Scotland OKs Elfabrio

Another Funding Win For Chiesi In Europe As Scotland OKs Elfabrio

Scotland’s health technology assessment body has agreed to reimburse Chiesi’s Elfabrio for Fabry disease, mirroring the decision from several other European countries – however, France turned down the rare disease drug, while Germany questioned its benefit.

Global Medtech Guidance Tracker: June 2024

Global Medtech Guidance Tracker: June 2024

Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 50 documents have been posted on the tracker since its last update.